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Abstract
The advent of next generation sequencing technologies (NGS) has expanded the area of genomic research, offering high
coverage and increased sensitivity over older microarray platforms. Although the current cost of next generation
sequencing is still exceeding that of microarray approaches, the rapid advances in NGS will likely make it the platform of
choice for future research in differential gene expression. Connectivity mapping is a procedure for examining the
connections among diseases, genes and drugs by differential gene expression initially based on microarray technology, with
which a large collection of compound-induced reference gene expression profiles have been accumulated. In this work, we
aim to test the feasibility of incorporating NGS RNA-Seq data into the current connectivity mapping framework by utilizing
the microarray based reference profiles and the construction of a differentially expressed gene signature from a NGS
dataset. This would allow for the establishment of connections between the NGS gene signature and those microarray
reference profiles, alleviating the associated incurring cost of re-creating drug profiles with NGS technology. We examined
the connectivity mapping approach on a publicly available NGS dataset with androgen stimulation of LNCaP cells in order
to extract candidate compounds that could inhibit the proliferative phenotype of LNCaP cells and to elucidate their
potential in a laboratory setting. In addition, we also analyzed an independent microarray dataset of similar experimental
settings. We found a high level of concordance between the top compounds identified using the gene signatures from the
two datasets. The nicotine derivative cotinine was returned as the top candidate among the overlapping compounds with
potential to suppress this proliferative phenotype. Subsequent lab experiments validated this connectivity mapping hit,
showing that cotinine inhibits cell proliferation in an androgen dependent manner. Thus the results in this study suggest a
promising prospect of integrating NGS data with connectivity mapping.
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Introduction
The next generation of sequencing technologies are expanding
our capabilities in modern cancer research. NGS offers such
advantages over the older constrained microarray approach in
increased sensitivity, not suffering from cross hybridisation and the
fact that no dependence on any prior knowledge is necessary, as
have been discussed in other articles [1–7]. The measurement of
the transcripts by this technique, RNA-Seq, has been steadily
growing as a method in recent years. The technique provides a
wealth of information on a cellular state and biological insight can
be obtained using appropriate pipelines for analysis [2,6,8]. The
millions of short reads from reverse transcribed RNA generated in
this process are sheared, and perhaps size selected, into
measurable strands of cDNA where ligated adapters are attached
for sequencing in single or paired-ends depending on the
experimental question [2].
The current sequencing platforms utilize different technologies
to try and achieve the same end goal with machines from Roche,
Illumina and Life technologies (plus arriving soon will be Ion
Torrents Proton) allowing for RNA-Seq analysis with sufficient
coverage [9]. The resulting output should be millions of reads of
data from 25 to 300 base pairs [2]. The typical process for NGS is
to align the millions of reads to a reference genome/transcriptome,
this reference can be supplemented with particular filtered
libraries. The aligners tend to fall within two categories, those of
Burrows Wheeler transform (such as BWA or BOWTIE) based
approach or those of a hash table (such as SHRIMP or SOAP)
based approach [10–13]. The choice of aligner is largely down to
performance versus complexity issues and have been addressed
before [1,14]. Once aligned or ’mapped’ to a genome the reads are
normally summarised and sorted or indexed to speed up
performance followed by a normalization step to allow sample
expression comparisons utilising differential expression where new
methods are arising all the time [15].
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Marioni et al. performed tests to compare the ability of
microarray technologies with that of the NGS method for
measuring steady state RNA to identify differentially expressed
genes [16]. They performed their analyses on liver and kidney
RNA samples and noted the RNA-Seq’s ability to perform with
little technical variation. They suggested at least an 81 percent
overlap between differentially expressed genes between platforms.
The RNA-Seq method, they furthered, offered more often than
not the true positives when the platforms differed, validated in a
laboratory setting by qPCR for a selection of genes declared
differentially expressed on one platform. They also found that the
RNA-Seq approach was highly reproducible and required fewer
technical replicates. Recently, Su et al. furthered this by examin-
ing the comparison of a microarray platform with an NGS
platform for the same set of toxicological samples. They found
similar gene expression profiles for both platforms with RNA-Seq
more sensitive at detecting low expressing genes. They found the
overlap of differential expression at upwards of 50 percent between
the two platforms but that RNA-Seq and microarray maintained a
consistent biological interpretation [17], with some of the non
comparable differential gene expression findings attributed to
RNA-Seq’s higher dynamic range in detection. RNA-Seq analysis
pipelines are being continually updated and evolving to the state
where EBI have supplied an extremely useful resource in an
Rcloud, including a tool ArrayExpressHTS [18], which is very
flexible in user choices.
Connectivity mapping is a bioinformatic technique to make
connections between disease, genes, and drugs and has been
implemented since 2006 by Lamb et al. [19] providing a valuable
resource which has also been successfully exploited with different
approaches and for different purposes, eg, for the construction of a
drug similarity network [20], or for assessing the regulatory activity
of a drug on its target genes [21]. The fundamental basis of a gene
expression connectivity map is the building of large scale reference
profiles that can be utilised against a signature gene set that would
best characterise the difference between two cellular states. The
reference profiles themselves are curated data based on a
particular drug - dose - cell line microarray analysis. The volume
of these reference profiles have increased vastly to over 6000,
providing an attractive database of compound-induced gene
expression profiles against which query gene signatures can be
compared. The hit compounds from connectivity mapping can be
ranked by an appropriate scoring metric to suggest candidate
therapeutics for the particular disease state from which the
signature was derived. sscMap was developed in 2008 by Zhang
and Gant [22–24] and represents an attractive model of the
connectivity mapping process. The technique has the added
statistical stringency to guard the results against false positives in
the analysis. A recent review on drug repositioning by Iorio et al.
describes the development in matching gene expression signatures
in order to connect phenotypes and the role of connectivity
mapping in reverting undesirable phenotypes. They suggested that
RNA-Seq may be an attractive approach to overcome the
limitations of microarray technology by having a large dynamic
range, as microarrays do not measure gene expression in absolute
units [25].
With the ability to obtain a list of differentially expressed genes
from both platforms for analysis, connectivity mapping may be
able to continue in the immediate future unabated until such a
time as when it becomes economically and scientifically viable to
create NGS reference profiles. Since essentially all that is required
for connectivity mapping is a list of the top ranked differentially
expressed genes, this can be obtained from an approach such as in
RNA-Seq analysis. Utilising an established analytic method [2] we
examined the possibility of analysing an established experiment
obtained from published fasta files. The data were in the format of
single end reads from an Illumina platform. The dataset pertained
to an androgen sensitive prostate cancer model by Li et al. [26]. In
order to make sure the therapeutic candidates were robust against
minor signature agitations, we applied the gene signature
perturbation method described previously [24]. This allows the
ranking of candidate compounds according to their ability to
withstand subtle changes and make them more reproducible
between researchers. We compared the results from RNA-Seq
gene signature against that from an experimentally similar
microarray dataset [27], and tested the top hit in a laboratory
setting. Figure 1 summarizes the key processing and integration
steps we followed in this study. This novel approach to analysing
RNA-Seq data will in no doubt be a highly desired approach in
cancer research where potential therapeutics are sought for
cancers with poor prognosis.
Materials and Methods
RNA-seq Dataset
The Li et al. prostate cancer dataset was directly obtained from
the Yeo laboratory website ( [26], http://yeolab.ucsd.edu/yeolab/
Papers.html). It contained seven Illumina samples S1–S7 which
represented four untreated and three treated samples of androgen-
sensitive human prostate adenocarcinoma LNCaP (Lymph Node
Carcinoma of the Prostate) cells which were androgen stimulated.
These sequences did not contain any quality scores with the
underlying sequence. The data contained within were 35
nucleotides in length and single-ended reads. RNA-Seq analysis
was performed as described by Oschlack et al. [2]. Briefly, the
tools are established for extraction of genes based on a Negative
Binomial model for differential expression. The aligner used was
BOWTIE (version 0.12.7) [10], with the reference genome ‘hg19’
downloaded from University of California, Santa Cruz(UCSC)
database [28]. This was extracted and stored in an folder located
by BOWTIE_INDEXES on a Linux machine. The standard
reference was used for analyses with no filtered databases applied
as this would be surplus to the connectivity mapping procedure.
BOWTIE alignments were run with the -best tags for the single-
end reads and -v3 command as it did not have quality scores with
the reads. The -f tag was also used as the files were in fasta format.
The dataset was run with -p4 and -sam command to allocate four
threads in the analysis stage and to obtain SAM outputs, all other
commands were left as standard.
Output SAM files containing the aligned reads are then
converted into BAM files using the samtools (version 0.1.8)
software with commands used to import, sort and index the files in
BAM format [29]. This lessens the memory footprint required
when using downstream analysis methods such as the R statistical
package for discovering differential expression. R is freely
downloadable software (http://www.r-project.org/) containing
many peer reviewed packages that can be used in different
biological statistical analyses.
The computational requirements to analyse RNA-Seq data are
intensive. The Li et al. prostate cancer study was performed on an
R-Cloud. The R-Cloud Analysis is an attractive avenue for
datasets that are particularly large and is offered by the European
Bioinformatics Institute. The EBIs R-Cloud allows up to 64Gig
computing servers for analysis of particularly large datasets under
an R environment. The platform offered ease of use and strong
technical support (http://www.ebi.ac.uk/Tools/rcloud/). The
resulting BAM files were uploaded to the R-Cloud (version
1.1.1) and imported into a dedicated 32Gig server
Connectivity Mapping with NGS Data
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(BENCH 32G_19 Tau) and the commands could be performed as
if on a local machine. Initially in R, we used the Bioconductor
package Rsamtools to obtain an interface for the BAM files
created. This is used with other R Bioconductor packages [30]
(such as IRanges and GenomicFeatures) that can be used to
manipulate the BAM files. GenomicFeatures has three classes
(GRanges, GRangesList, and GappedAlignments) and is used to
represent the genomic locations. In the datasets analysed the
GRanges class was set as ambiguous for the strand designator.
From here, the BAM files are analysed by GenomicFeatures.
Briefly, this package retrieves and manages transcript-related
features which utilises the RNA-Seq data with resources from
UCSC Genome Bioinformatics and BioMart. It creates a
’TranscriptDb’ object to store transcript metadata and in this
study the ’makeTranscriptDbFromUCSC’ command was used on
the ’hg19’ genome with the supported track of Ensembl genes.
Further to this we use the ’transcriptsby’ command to maintain the
relationships of the transcripts to a biological context, here we use
’transciptsBy’ with the type of feature grouping factor ’gene’. The
locations and identifiers are now contained in a GRangesList. The
’countOverlaps’ function contained in the GenomicRanges
package can now be used to count the overlaps for each read in
the query. With the data summarized into a table of counts we
then used DESeq to create our list of differentially expressed genes
as DESeq is good at small sample sizes by borrowing strengths
from closely related genes statistically, first estimating sizefactors
and then estimate dispersions followed by the negative binomial
test and order the results [31]. As a comparison to the results of
DESeq, EdgeR was also used to analyse the data to obtain lists of
differentially expressed genes utilizing the TMM method to supply
appropriate scaling factors and then this is incorporated into the
DGEList with an ’estimateCommonDisp’ method applied fol-
lowed by exactTest [32], which is a generalization of the exact
binomial test. The topTags command was used to extract the top
differentially expressed genes with a chosen level of statistical
significance.
Figure 1. Flow chart of processing stages involved in establishing signatures from RNA-Seq and Microarray analysis for
connectivity mapping.
doi:10.1371/journal.pone.0066902.g001
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Microarray
Microarray data were downloaded from a study by Wang et al
[27] (GEO Accession Number GDS3111), which looked into a
hierarchical network of transcription factors that would govern
androgen receptor-dependent prostate cancer growth. There were
nine files in this study which were downloaded from GEO by the
Accession GSE7868 in zipped format into a folder and extracted.
This contained nine CEL files which encapsulated three replicates
of increasing time exposure to androgen stimulation by DHT over
0, 4 and 16 hrs. Initial analysis was carried out using GEOs
Dataset Browser which allowed graphical representation of the
genes in the list [33,34]. Analysis of the data was carried out using
R packages SamR(v2.0) [35], affy(v1.34.0) [36], and genefil-
ter(v1.38.0) [37] with their associated dependencies. The nine files
were analysed by affy’s justRMA() and their expression status
extracted. We then used the package genefilter to remove the
genes with small variance across all the files by filtering from the
median. With the small size in samples we utilised the package
SamR to extract differentially expressed genes. The differential
groups were 0 hrs and 16 hrs, using a median FDR threshold of
0.05 obtained by two class unpaired test, random seed and 100
permutations. Genes from high and low tables were copied to
Microsoft Excel for inspection and formulation of a gene signature
for connectivity mapping.
sscMap
Connectivity map analysis was performed using the sscMap
software [22,23], which is a stand alone Java application running
across different Operating Systems. The connectivity mapping
approach requires three key components: query gene signature,
reference profile database, and pattern matching algorithm. At the
heart of the original CMap and later sscMap, is a core database of
reference gene expression profiles derived from large scale
systematic microarray experiments by the Broad Institute. The
current release of the Broad Institute Connectivity Map (Build 02)
(http://www.broad.mit.edu/cmap/) contains over 6000 individu-
al reference profiles, and so does the sscMap, whose core database
of reference profiles was created using the same raw microarray
datasets. Details on the procedures and guiding principles of
constructing reference profiles can be found in papers that
introduced the frameworks, for CMap [19] and for sscMap
[22,23], respectively. The sscMap application with gene signature
perturbation capacity can be freely downloaded from
ftp://ftp.qub.ac.uk/pub/users/sdzhang/perturbation. Bundled
with the downloads are detailed description and guided tours on
how to use the software and interpret the results. The query gene
signatures used in this study are derived from the results of
differential expression analysis on the RNA-seq data and
microarray data. The differentially expressed list of genes returned
by topTags from DESeq were mapped to Affymetrix HG-U133A
Probeset IDs before feeding to sscMap. An assortment of signature
sizes were run in sscMap with a large number (105) of
randomization and permutations conducted to gauge statistical
significance. These lists served as a bench mark to find an optimal
size of the gene signature where a FDR threshold (0.01) is met with
the minimum number of genes. The gene signature with optimal
size, n, was then run again in sscMap with the gene signature
perturbation procedure. This allows us to measure the stabilities of
the discovered connections by their ability to withstand a series of
single gene omission with replacement. The candidate compounds
that withstood these perturbations received a score quantifying
their perturbation stability [24]. We also carried out connectivity
mapping analysis on the microarray data, taking as input the
differentially expressed genes detected by SamR between the time
points 0 hrs and 16 hrs. As this microarray dataset was based on
Affymetrix HG-U133 Plus 2.0 microarray platform, we filtered out
Figure 2. sscMap output for the signature from the RNA-Seq dataset. Figure demonstrates the volcano plot of the distribution of candidate
compounds that may enhance (right side) or suppress (left side) the phenotype. Significant candidates are above the green line.
doi:10.1371/journal.pone.0066902.g002
Connectivity Mapping with NGS Data
PLOS ONE | www.plosone.org 4 June 2013 | Volume 8 | Issue 6 | e66902
T
a
b
le
1
.
D
ES
e
q
to
p
ra
n
ki
n
g
d
if
fe
re
n
ti
al
ly
e
xp
re
ss
e
d
g
e
n
e
s.
E
n
se
m
b
lI
D
G
e
n
e
S
y
m
b
o
l
M
e
a
n
-s
ti
m
u
M
e
a
n
-u
n
st
im
u
ra
ti
o
(s
ti
m
u
/
u
n
st
im
u
)
lo
g
2
R
a
ti
o
p
v
a
lu
e
a
d
ju
st
e
d
P
v
a
lu
e
D
S
e
q
P
o
si
ti
o
n
a
ff
y
M
a
p
p
e
d
ID
EN
SG
0
0
0
0
0
1
5
1
5
0
3
N
C
A
P
D
3
3
7
2
5
.0
6
7
8
.0
4
4
7
.7
3
5
.5
8
0
.0
0
E
+0
0
0
.0
0
E+
0
0
1
2
1
2
7
8
9
at
EN
SG
0
0
0
0
0
0
9
6
0
6
0
FK
B
P
5
1
6
0
5
.8
5
4
7
.3
2
3
3
.9
4
5
.0
8
0
.0
0
E
+0
0
0
.0
0
E+
0
0
2
2
0
4
5
6
0
at
EN
SG
0
0
0
0
0
1
1
6
1
3
3
D
H
C
R
2
4
1
9
9
7
.4
2
1
9
2
.4
2
1
0
.3
8
3
.3
8
0
.0
0
E
+0
0
0
.0
0
E+
0
0
3
2
0
0
8
6
2
at
EN
SG
0
0
0
0
0
1
5
6
6
8
9
G
LY
A
T
L2
1
6
5
2
.5
2
1
5
7
.7
2
1
0
.4
8
3
.3
9
1
.8
3
E-
3
1
7
1
.4
7
E-
3
1
3
4
n
o
t
Fo
u
n
d
In
A
n
n
o
ta
ti
o
n
Fi
le
EN
SG
0
0
0
0
0
1
1
3
5
9
4
LI
FR
1
0
3
0
.6
4
5
4
.4
4
1
8
.9
3
4
.2
4
7
.3
3
E-
3
1
1
4
.7
2
E-
3
0
7
5
2
0
5
8
7
6
at
EN
SG
0
0
0
0
0
1
6
6
4
5
1
C
EN
P
N
7
5
2
.5
7
2
2
.1
5
3
3
.9
8
5
.0
9
3
.9
6
E-
2
9
9
2
.1
2
E-
2
9
5
6
2
1
9
5
5
5
s
at
,
2
2
2
1
1
8
at
EN
SG
0
0
0
0
0
1
1
5
6
4
8
M
LP
H
2
7
3
3
.9
6
4
2
2
.6
1
6
.4
7
2
.6
9
2
.8
1
E-
2
8
6
1
.2
9
E-
2
8
2
7
2
1
8
2
1
1
s
at
EN
SG
0
0
0
0
0
2
4
4
3
2
4
R
P
1
1
-6
7
L3
.6
8
8
4
.9
5
7
3
.7
3
1
2
.0
0
3
.5
9
7
.9
7
E-
2
3
5
3
.2
1
E-
2
3
1
8
n
o
t
Fo
u
n
d
In
A
n
n
o
ta
ti
o
n
Fi
le
EN
SG
0
0
0
0
0
1
1
6
2
8
5
ER
R
FI
1
6
4
2
.0
6
3
3
.4
4
1
9
.2
0
4
.2
6
1
.4
4
E-
2
2
6
5
.1
4
E-
2
2
3
9
n
o
t
Fo
u
n
d
In
A
n
n
o
ta
ti
o
n
Fi
le
EN
SG
0
0
0
0
0
1
3
0
0
6
6
SA
T
1
1
0
4
9
.4
3
1
3
8
.1
2
7
.6
0
2
.9
3
3
.5
8
E-
1
9
7
1
.1
5
E-
1
9
3
1
0
2
1
3
9
8
8
s
at
,
2
1
0
5
9
2
s
at
,
2
0
3
4
5
5
s
at
T
h
e
to
p
1
0
g
e
n
e
s
th
at
w
e
re
re
tr
ie
ve
d
b
y
D
ES
e
q
u
si
n
g
th
e
R
-C
lo
u
d
o
n
EB
I
fo
r
th
e
LN
C
aP
d
at
as
e
t.
Ex
p
re
ss
io
n
ra
ti
o
is
(s
ti
m
u
la
te
d
/u
n
-s
ti
m
u
la
te
d
).
Se
e
T
ab
le
S1
fo
r
th
e
fu
ll
lis
t
o
f
d
if
fe
re
n
ti
al
ly
e
xp
re
ss
e
d
g
e
n
e
s
re
tu
rn
e
d
b
y
th
e
D
ES
e
q
an
al
ys
is
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
6
6
9
0
2
.t
0
0
1
Connectivity Mapping with NGS Data
PLOS ONE | www.plosone.org 5 June 2013 | Volume 8 | Issue 6 | e66902
Probeset IDs that are not part of HG-U133A arrays before feeding
the gene signature to sscMap. This list of DEGs were processed in
the same fashion as described above.
GeneCodis Analysis
The gene lists obtained from both the NGS gene signature and
the microarray gene signature were combined and submitted to
GeneCodis [38,39], an on-line modular enrichment tool. Gene-
Codis assesses if an input list of genes results in combinations of
annotations that are significantly enriched. For this analysis, the
following annotations were selected: GO Biological Process, GO
Molecular Function, GO Cellular Component, KEGG Pathways,
InterPro Motifs, Panther Pathways and Transcription Factors. Of
particular interest were processes and pathways in which genes
identified from both the NGS and microarray analyses partici-
pated in.
Laboratory Analysis
Materials. Cell lines were maintained in RPMI media
containing 10% FBS and cultured at 37.0uC in a 5% carbon
dioxide incubator under aseptic conditions. Cotinine (Cat #
C5923) was purchased from Sigma (Dorset, UK), dissolved in
ethanol, aliquoted and stored at 220uC.
Proliferation assay. Cells were seeded in triplicate at 50,000
cells per well in 6-well plates and allowed to attach overnight.
Media containing the appropriate concentration of cotinine was
added to each well. Fresh media with cotinine was replaced after
48 hours. Cell counts were carried out at 96 hours post treatment.
Following treatment cells were trypsinised and resuspended in
equal volumes of growth medium. 500ml of cell suspension was
diluted with 100ml of 0.1% trypan blue staining solution (Sigma)
and allowed to incubate at room temperature for 5 minutes.
Viable cells were then counted using a hemocytometer. Viable cell
Table 2. EdgeR top ranking differentially expressed genes.
EnsemblID GeneSymbol log2Ratio adjustedP EdgeRposition affy Mapped ID DSeqPosition
ENSG00000151503 NCAPD3 5.58 0 1 212789 at 1
ENSG00000096060 FKBP5 5.10 0 2 204560 at 2
ENSG00000166451 CENPN 5.09 0 3 219555 s at, 222118 at 6
ENSG00000113594 LIFR 4.24 0 4 205876 at 5
ENSG00000244324 RP11-67L3.6 3.60 0 5 not Found In
Annotation File
8
ENSG00000156689 GLYATL2 3.40 0 6 not Found In
Annotation File
4
ENSG00000116133 DHCR24 3.38 0 7 200862 at 3
ENSG00000155368 DBI 3.01 0 8 (202428 x at, 209389 x at,
211070 x at)
22
ENSG00000130066 SAT1 2.93 0 9 213988 s at, 210592 s at,
203455 s at
10
ENSG00000115648 MLPH 2.72 0 10 218211 s at 7
The top 10 genes that were retrieved by EdgeR using the R-Cloud on EBI for the LNCaP dataset. Expression ratio is (stimulated/un-stimulated). Here we can see that the
same set of identifiers used in the sscMap from the DESeq analysis would have been attained by EdgeR with the exception of ENSG00000155368 which was ranked
22nd in DESeq analysis. Table S2 contains the full list of differentially expressed genes returned by the EdgeR analysis.
doi:10.1371/journal.pone.0066902.t002
Table 3. The gene signature from the NGS dataset using DESeq analysis and their positions in the microarray DEGs by SamR.
ProbeSetID GeneSymbol EnsemblID log2Ratio adjustedPvalue DESeqPosition SamRposition SamRlog2FC
SamRq-
value(%)
212789 at NCAPD3 ENSG00000151503 5.58 0 1 96 1.23 0.00
204560 at FKBP5 ENSG00000096060 5.08 0 2 30 2.04 0.00
200862 at DHCR24 ENSG00000116133 3.38 0 3 91 1.14 0.00
205876 at LIFR ENSG00000113594 4.24 4.72E-307 5 374 0.68 0.89
219555 s at CENPN ENSG00000166451 5.09 2.12E-295 6 29 1.93 0.00
222118 at CENPN ENSG00000166451 5.09 2.12E-295 6 11 2.58 0.00
218211 s at MLPH ENSG00000115648 2.69 1.29E-282 7 913 0.47 3.09
203455 s at SAT1 ENSG00000130066 2.93 1.15E-193 10 146 0.95 0.32
210592 s at SAT1 ENSG00000130066 2.93 1.15E-193 10 161 0.91 0.32
213988 s at SAT1 ENSG00000130066 2.93 1.15E-193 10 148 0.95 0.32
The list of identifiers and their associated genes extracted from the NGS dataset using DESeq analysis and put to the sscMap. We established where these genes were
located in full list (Table S3) of statistically differentially expressed genes returned by the SamR analysis on the microarray dataset. All these genes lay within a SamR
reported FDR of 3:09%. Table S4 also contains the signed ranks of these 10 probesetIDs in the 6 instances of reference profiles for cotinine.
doi:10.1371/journal.pone.0066902.t003
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counts for each treatment arm were plotted as viable cell counts
relative to the control. Error bars represent standard deviation of
counts in triplicate.
Cell doubling time assay. Cells were seeded in triplicate at
20,000 cells per well in 16 well xCELLigence E-plates from Roche
and run on the xCELLigence system which provides real-time cell
numbers across a give time frame. Specified drug treatments were
carried out as for cell proliferation assay. The relative cell doubling
time was calculated using the in-built software. Cell proliferation
and cell doubling experiments were carried out 3 times
independently using different cell stock batches.
Statistical analysis. The unpaired two-tailed t-test was used
to determine statistically significant differences between treatment
effects using Prism Graphpad software.  denotes p v 0.01.
Results
Differential Expression and sscMap Analysis
Table 1 and 2 list the top 10 differentially expressed genes
returned from DESeq and EdgeR on the same RNA-seq dataset
from the Yeo laboratory [12]. For the full list of differentially
expressed genes returned by the DESeq and EdgeR analysis,
please see Table S1 and Table S2, respectively. The overlap
between the two top-10 lists is 9 out of l0. DESeq and EdgeR are
both popular tools for differential expression analysis on RNA-seq
data. Our results here suggest that their agreement is very high as
far the top selected genes are concerned. Therefore, in subsequent
sscMap analysis we chose the list of differentially expressed genes
from DESeq to make query gene signatures, as DESeq was shown
to make more balanced selection of differentially expressed genes
throughout the dynamic range [31]. In connectivity mapping our
focus is on the top selected genes as they will be used to form the
query gene signature as input to sscMap. DESeqs top ranking
genes were extracted and converted to Affymetrix Probeset IDs
that would be usable in the sscMap software. The optimal
signature size for sscMap is obtained by increasing the signature
size until a set of statistically significant connections with an FDR
ƒ1% are first returned. In the current case of the RNA-seq data
set, a gene signature with the top 10 mapped Affymetrix Probeset
IDs (listed in Table 3) was determined to be an optimal length.
Table 3 lists these 10 probeset IDs in the gene signature, and also
shows the positions of these genes in the results of SamR analysis
on the microarray dataset. Once acquired this gene signature was
fed to sscMap with the gene signature perturbation procedure,
which would check all the candidate compounds for their
robustness against single gene omission. With this we can rank/
prioritize the candidate compounds by their statistical significance,
perturbation stability and their replicate number in the reference
profile database. The criteria involved in order to fine filter the
candidates was first by whether the p-value was significant with
sscMaps Bonferonni correction, then if these candidates were
significant by their perturbation stability which resided between
zero to one. A perturbation stability score of one would indicate
that the candidate compound remained significantly connected to
Figure 3. NGS signature genes explored in Microarray study. The set of genes utilised in the NGS gene signature for sscMap are explored in
the GEO Dataset Browser with the Wang et al microarray dataset.
doi:10.1371/journal.pone.0066902.g003
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the gene signature during all the perturbations. The list of mapped
Affymetrix Probeset IDs in Table 3 represent seven different
genes. This gene signature returned 271 compounds with
statistically significant connections to it (Figure 2), of which 122
had a perturbation stability of 1 with which we would then sort by
their setsize, which is the number of replicate reference profiles in
the database for this compound. For equal setsizes, the compounds
would then be sorted by their setscore to the gene signature. A
negative setscore indicates that the compound is inversely
connected to the gene signature, and may be useful to inhibit
the phenotype represented by the signature. The top 2 ranking
compounds in the list was haloperidol with a setsize of 32 and a
setscore of 0.228 and genistein with a setsize of 17 and a setscore of
0.353. sscMap predicts that these compounds to have a high
probability in enhancing the phenotype. The top candidate
compounds that sscMap predicts could suppress the phenotype
are nifedipine with a setsize of 7 and a setscore of 20.297 and
cotinine with a setsize of 6 and a setscore of 20.598.
Utilising the microarray dataset from Wang et al. that had 0 hr,
4 hr and 16 hr treated LNCaP cells, with the GEO dataset
browser we can extract the graphs for each of the ten gene
identifiers in Table 3, all of which depict an increase in expression
after 16 hrs treatment in the microarray dataset (Figure 3). The
microarray analysis of the U133A plus 2 arrays by SamR revealed
a list of differentially expressed genes that were extracted by a
stringent threshold after genefilter removed half of the genes that
had the lowest variance. The U133A Plus 2 array after genefilter
were reduced from 54,675 probes to 27,337. From here, we used
the 0 hr versus 16 hr data to analyse by SamR. Utilising the delta
table we selected the first median FDR value closest to 0.05, ie, a
median FDR threshold of 0.068, which gave a delta value of
0.0841, as our stringency threshold. This returned a list of 1313
genes as significant. We then examined if the genes extracted from
NGS for sscMap would have been within this stringent list of
U133A Plus 2 identifiers (See Table S3 for the full list of
differentially expressed genes from the EdgeR analysis). We found
all ten genes present, and present within an FDR of 0.0309. Three
of the NGS top ten Probesets are within the top 30 most
differentially expressed by U133A Plus 2 array, two CENPN
identifiers and one FKBP5 identifier (see Table 3), which are
viewed with the GEO Dataset Browser in Figure 3.
The top genes from the microarray analysis were extracted and
put to connectivity mapping with the same procedures as above.
In order to achieve an FDR of ƒ1%, the top 51 genes were
extracted and used in mapAffy which returned 23 Affymetrix HG-
U133A probeset IDs. These 23 Affy probeset IDs composed the
gene signature from the microarray dataset, and they are listed in
Table 4 together with the corresponding results from DESeq
analysis on the NGS dataset. This gene signature with 23
Affymetrix IDs and their associated expression status were put to
the sscMap for perturbation analysis. The results for this gene
signature (Figure 4) were that 154 compounds were declared
significant with 64 of them having full perturbation stability. The
top ranking compounds that would potentially enhance the
phenotype were furazolidone with a setsize of 4 and a setscore
of 0.344 and PF-00539745-00 with a setsize of 3 and a setscore of
0.341, and those that would potentially suppress the phenotype
were indometacin with a setsize of 8 and a setscore of 20.227 and
cotinine with a setsize of 6 and a setscore of 20.377.
We contrasted those 64 compounds with full perturbation
stability from the microarray dataset against those 122 compounds
from RNA-Seq dataset, the overlap between these two lists of
compounds is 18, which are itemized in Table 5. We also carried
out a hypergeometric test to gauge the statistical significance of
having 18 overlapping drugs between two lists (respectively of 64
and 122 drugs) on a population of 1309 drugs from the sscMap
Figure 4. sscMap output for the signature from the Microarray dataset. Distribution of candidate compounds that may enhance (right side)
or suppress (left side) the phenotype of the Microarray study.
doi:10.1371/journal.pone.0066902.g004
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database. The result is highly significant, with a p-value of
7:6|10{6. This result indicated a high level of compatibility
between the two different technologies, at least for the purpose
gene expression connectivity mapping to establish/reveal the
biological connections. The RNA-Seq gene signature generally
yielded setscores with higher magnitude compared to that of the
microarray signature. In each case of these 18 compounds, there
was one hundred percent concordance in the direction of their
setscores declaring what role (enhancing or suppressing) they
would play in influencing the phenotype represented by the
signatures. Of these 18 overlapping compounds cotinine was
ranked the top in both the NGS and microarray based results, and
we chose this compound for laboratory validation of its inhibitory
effects on the proliferative phenotype. For the NGS gene
signature, Table S4 contains the signed ranks of its 10 probesetIDs
in the 6 instances of reference profiles of cotinine, whereas similar
information can be found in Table S5, for the 23 probesetIDs of
the microarray gene signature.
GeneCodis Analysis
GeneCodis analysis was conducted on the list of differentially
expressed genes from the NGS dataset gene signature (Table 3)
and the microarray dataset gene signature (Table 4). Twenty-two
sets of processes were significantly enriched, with a corrected
hypergeometric p-value of less than 0.05 (Table 6). Thirteen out of
these twenty-two significantly enriched processes involved over-
lapping genes from the NGS signature and the microarray
signature.
Laboratory Confirmation
Cotinine, the nicotine metabolite, is commonly found in
tobacco and is an inhibitor of 3 alpha- hydroxysteroid dehydro-
genase (HSD) which converts DHT to 3 alpha-androstanediol.
Stimulation of LNCaP cells with DHT would selectively activate
this androgen related pathway in these cells, causing an increase in
proliferation rates, while pre-treatment with cotinine would clearly
block the activation of this pathway. The appearance of cotinine as
the top candidate which could suppress the phenotype of DHT
stimulation in the androgen-sensitive LNCaP cell line highlight the
reliable nature of the connectivity mapping procedure given that
the dataset was obtained from androgen stimulated cells.
To biologically test the relevance of the top candidate drug we
carried out cell proliferation, viability and cell doubling assays
either in the absence or presence of cotinine at doses which have
been used in the literature on the androgen dependent LNCaP
cells and compared these results with the androgen independent
PC3 cells. The PC3 cells were chosen as this cell line is no longer
dependent on the pathways which cotinine will inhibit, therefore
Table 4. The gene signature from the microarray dataset using SamR analysis.
ProbeSetID GeneSymbol log2FoldChange
SamR-q-
value(%) SamRposition DESeqPosition log2Ratio adjustedPvalue
209854 s at KLK2 3.84 0 1 15 3.18 5.77E-160
210339 s at KLK2 3.48 0 2 15 3.18 5.77E-160
205041 s at ORM1/ORM2 3.78 0 3 NA NA NA
211689 s at TMPRSS2 3.12 0 4 18 2.26 8.87E-130
222118 at CENPN 2.58 0 11 6 5.09 2.12E-295
217875 s at PMEPA1 2.38 0 13 142 2.99 1.4E-30
205862 at GREB1 2.36 0 14 1356 1.00 0.000149717
219049 at CSGALNACT1 2.21 0 15 1061 1.81 0.0000119
205102 at TMPRSS2 2.07 0 16 NA NA NA
204583 x at KLK3 1.96 0 20 31 1.81 1.14E-102
204582 s at KLK3 2.02 0 21 31 1.81 1.14E-102
209706 at NKX3-1 1.95 0 22 36 2.49 2.59E-90
219555 s at CENPN 1.93 0 29 6 5.09 2.12E-295
204560 at FKBP5 2.04 0 30 2 5.08 0
203196 at ABCC4 1.69 0 33 23 2.85 5.94E-117
221584 s at KCNMA1 1.57 0 35 85 2.16 2.31E-43
204897 at PTGER4 1.62 0 37 671 3.53 0.000000015
211548 s at HPGD 1.60 0 38 185 DIV0! 3.19E-25
220014 at PRR16 1.50 0 44 NA NA NA
219476 at C1orf116 1.47 0 46 96 1.94 5.44E-39
203180 at ALDH1A3 1.46 0 48 668 1.29 1.44E-08
210787 s at CAMKK2 1.42 0 49 NA NA NA
201110 s at THBS1 1.38 0 51 NA NA NA
The list of identifiers and their associated genes extracted from the microarray using SamR analysis and put to the sscMap. 18 out these 23 gene identifiers are also
identified as differentially expressed genes (DEGs) by the DESeq analysis on the NGS dataset (Table S1). NA indicates that the corresponding gene was not returned as
DEG by DESeq and hence is not found in Table S1. Expression fold change is defined as ratio (stimulated/unstimulated).  Note that Dseq reported 0 expression for this
gene in the unstimulated state, hence ratio(stimulated/unstimulated) and logratio are not defined. Table S5 also contains the signed ranks of these 23 probesetIDs in
the 6 instances of reference profiles for cotinine.
doi:10.1371/journal.pone.0066902.t004
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unlike the LNCaP cells, the proliferation of these cells should not
be affected by cotinine. Indeed, we found that the compound
significantly inhibited overall cell proliferation of the LNCaP cell
line but not that of the PC3 at the doses used (Figure 5A). The
reduction in cell proliferation was attributed to an increased cell
doubling time following cotinine treatment (Figure 5B), which
would reduce overall cell numbers in the treated group. These
findings may be even more significant given that this was carried
out in the absence of any external androgen stimulation as we
would assume that the stimulation of these cells with DHT would
further activate the pathway, causing increased proliferation,
which could then be blocked by the cotinine.
Discussion
The phenotype of androgen stimulation in androgen-sensitive
cell lines has long been known to result in increased proliferation
rates through, in part, androgen receptor translocation to the
nucleus and activation of transcription resulting in cell growth,
although the complete mechanism remains to be characterised.
The results of this study demonstrated a strong overlap of
candidate compounds which could be used to influence the
phenotype in a laboratory setting. We were able to show the same
compound could be detected from both platforms that represented
the best opportunity to suppress the phenotype, which in this case
is androgen driven cell proliferation. Tested in the laboratory,
cotinine, was shown to be able to inhibit proliferation in LNCaP
cells but not in the PC-3 controls. These effects were found to be
mainly due to decreased proliferation and cell division rates
(Figure 5) and not due to increased cell death in the treated
samples as no evidence of increased numbers of non-viable cells
were found (data not shown). The full effects on the transcriptome
of LNCaP cells following cotinine treatment either in the absence
or presence of an external androgen stimulant, such as DHT or
R1881, would no doubt give further insights into the mechanism
of proliferation inhibition.
There is scientific precedence for using cotinine as an anti-
proliferative drug in a hormone sensitive setting. In an in vitro
study choriocarcinoma cells, which are germ cell tumour cells
arising in the testis or ovary, were exposed to increasing
concentrations of cotinine and examination of serum hormone
levels was carried out. Addition of cotinine inhibited estradiol
accumulation in choriocarcinoma cells at micromolar concentra-
tions [40]. It was also noted that exposure to cotinine in placental
microsomes from term females gave a similar response as the drug
aminoglutethimide, which is an inhibitor of aromatase that is used
clinically in the hormonal therapy of metastatic breast cancer. The
functional similarity of these compounds may be explained by the
substantial chemical structural similarities that they share. Another
study also confirmed that exposure to cotinine functioned in a
competitive manner to inhibit testosterone biosynthesis in rat cells
[41]. In a recent clinical study of healthy females it was concluded
that smoke exposure was associated with lower than normal
median steroid hormone concentrations. In general non-smokers
tended to have higher median hormone concentrations than
smokers and passive smokers. In the particular case of androgens,
when classified by serum cotinine levels, it was noted that the
median concentrations of testosterone, cortisol, and androgen
steroid hormone analytes were highest in non-smokers who would
have lower cotinine serum levels compared to smokers [42].
The p38 inhibitor SB-202190, which was another candidate
compound from the connectivity mapping list, is a highly selective
Table 5. Compounds declared significant between both technologies that had full perturbation stability.
refsetname setsize queryName queryLength setscore sig Per refsetname setsize queryName queryLength setscore sig Per
cotinine 6 RNA-seq 10 20.598 1 1 cotinine 6 Microarray 23 20.377 1 1
morantel 5 RNA-seq 10 20.557 1 1 morantel 5 Microarray 23 20.366 1 1
tobramycin 4 RNA-seq 10 20.671 1 1 chlorphenesin 4 Microarray 23 20.398 1 1
trioxysalen 4 RNA-seq 10 20.658 1 1 trioxysalen 4 Microarray 23 20.383 1 1
pentoxyverine 4 RNA-seq 10 20.601 1 1 trimetazidine 4 Microarray 23 20.370 1 1
levamisole 4 RNA-seq 10 20.569 1 1 pentoxyverine 4 Microarray 23 20.369 1 1
trimetazidine 4 RNA-seq 10 20.552 1 1 levamisole 4 Microarray 23 20.356 1 1
chlorphenesin 4 RNA-seq 10 20.548 1 1 lysergol 4 Microarray 23 20.349 1 1
oxprenolol 4 RNA-seq 10 20.535 1 1 tobramycin 4 Microarray 23 20.348 1 1
zomepirac 4 RNA-seq 10 20.533 1 1 oxprenolol 4 Microarray 23 20.336 1 1
lysergol 4 RNA-seq 10 20.505 1 1 zomepirac 4 Microarray 23 20.330 1 1
fosfosal 4 RNA-seq 10 20.428 1 1 fosfosal 4 Microarray 23 20.280 1 1
sertaconazole 4 RNA-seq 10 20.411 1 1 sertaconazole 4 Microarray 23 20.256 1 1
abamectin 4 RNA-seq 10 20.392 1 1 abamectin 4 Microarray 23 20.245 1 1
saquinavir 4 RNA-seq 10 20.359 1 1 saquinavir 4 Microarray 23 20.243 1 1
ipratropium
bromide
3 RNA-seq 10 20.564 1 1 ipratropium
bromide
3 Microarray 23 20.365 1 1
furazolidone 4 RNA-seq 10 0.602 1 1 furazolidone 4 Microarray 23 0.344 1 1
5186223 1 RNA-seq 10 0.701 1 1 5186223 1 Microarray 23 0.504 1 1
The list of compounds that overlapped between the two technologies, which was 18 out of a possible 64. 16 of the 18 compounds were candidates that would
potentially suppress the phenotype. queryLength is the number of genes included in the query gene signature. refset is the set of reference profiles for a compound in
the cmap database; Setsize is the size of the set of Reference Profiles for that compound in the cmap core database. sig = 1 indicates the connection score is statistically
significant; Per = 1 means that the connection has full perturbation stability.
doi:10.1371/journal.pone.0066902.t005
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and cell permeable inhibitor which has also been shown to
specifically inhibit the androgen pathway in LNCaP cell lines. P38
is a signalling protein and a member of the mitogen-activated
protein kinase (MAPK) pathway. MAPK signalling has long been
associated with cancer initiation and progression in a number of
disease settings and indeed the role of P38 has been well illustrated
in the progression of prostate cancer [43]. There have been
numerous investigations into the role of P38 in androgen
responsive gene activation and prostate cancer progression.
Pretreatment of LNCaP cells with SB-202190 could inhibit
androgen receptor mediated activation of the PSA promotor by
IL-6, a factor which is known to promote prostate cancer growth.
The same group also noted that treatment of LNCaP cells with
either IL-6 or DHT caused nuclear translocation of the androgen
receptor another key process involved in androgen responsiveness,
which would be halted by SB-202190 pre-treatment [44].
Inhibition of the P38 pathway in this setting would therefore
reverse the effects observed with DHT stimulation again
confirming the results of the connectivity mapping.
Another prostate cancer study in Oncogene using SB-202190
found that formation of fibroblast growth factor (FGF) induced
Figure 5. Cotinine was the top candidate compound to
suppress the proliferative phenotype. Validation of cotinine as
the top candidate to suppress cell proliferation phenotype induced via
androgen pathway. A, Cells in 6 well plate format were treated with
vehicle or various doses of cotinine for 96 hours. Total viable cell
numbers were counted by haemocytometer. Cell counts are represent-
ed as relative to the untreated control value. B, Cells were treated with
indicated doses of cotinine and seeded in xCELLigence 16 well E-plates.
Real-time analysis of cell doubling rates was recorded and rate of
doubling between 72–96 hours was plotted relative to untreated
control using the system software. The experiment was repeated three
times with similar results. ** denotes pv0:01 using unpaired two-tailed
t-test.
doi:10.1371/journal.pone.0066902.g005
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actin stress fibres could be abolished using this inhibitor. These
cytoskeletal changes are of importance in the progression of the
disease and these factors are known to be over-expressed in human
prostate cancer. This work highlights the p38-dependent nature of
this progression, again confirming the validity of SB-202190 on
the connectivity list [45].
The other compounds on the list, belonging to the NSAID
family, are of interest at present given the recent numerous
publications linking this class of drugs with anti-cancer effects.
There is substantial evidence to suggest that regular use of
NSAID’s can reduce an individual’s risk of developing a number
of cancers. Recent studies have shown that NSAID’s can be
beneficial as they can induce cell death and inhibit epidermal
growth factor receptor signalling via the MAPK pathway in colon
cancer [46]. Another study again highlighted the pro apoptotic
effects of NSAID treatment via inhibition of protein synthesis in
colon cancer and a number of other cancer cell types [47]. Their
use has again been in the clinical spotlight with the recent
publication re-opening the debate of their benefits as an adjuvant
therapy and also the anti-cancer properties of NSAID’s in patients
with Lynch Syndrome were published recently [48].
GeneCodis highlighted a number of overlapping sets of
processes which were identified by either the NGS or microarray
analysis or both sets of data (Table 6). Given the high concordance
of the top differentially expressed genes identified using both
datasets it was unsurprising to find significant enrichment of 13 out
of 22 of the processes driven by NGS/microarray overlapping
genes using the GeneCodis analysis. The overlapping nature of the
signatures and processes can also be attributed to the fact that both
datasets are derived from comparison of DHT stimulated or un-
stimulated androgen responsive prostate cancer cells. The
resulting genes that were differentially expressed would all have
been due to activation of the androgen pathway and the candidate
compounds that were top of the connectivity mapping would
specifically block one of these components. These findings further
confirm the robustness of the connectivity mapping technique in
identifying candidate compounds to inhibit a targeted phenotype.
One point worth noting is that the two datasets used have
limited sample size, particularly for the microarray dataset 3 vs 3
samples is small, although for the RNA-seq data set 3 vs 4 samples
is moderate considering the current literature norm. On the other
hand, the two datasets were both from cell line based experiments;
Unlike human patient samples, cell line experiments are much less
heterogenous and hence less demanding on sample sizes. That
said, the important safeguard in our analysis is that we applied
very stringent criteria in differential expression analysis to exert
effective control of false discoveries. Another compensating factor
for the small sample sizes is that for connectivity mapping
purposes, we often only need a small set of very significant top
DEGs (differentially expressed genes) to establish/reveal the
biological connections, and thus the demand on sample sizes can
be alleviated to some extent. A noisy factor that may affect the
comparison between the two datasets is that although the two
studies are both related to prostate cancer, the study goal and
process are slightly different. In spite of this, the highly significant
overlap between the two connectivity mapping exercises is really
encouraging for such integrative approach in future studies.
The results we presented in this work points to a promising
prospect of integrating RNA-seq data with connectivity mapping.
But it is also important point out the limitation of this approach.
Reference profiles in the current connectivity mapping databases
were all built on microarray technology, which may have been
limited by its dynamic range, sensitivity and potential bias towards
the pre-defined probes. RNA-seq on the other hand provides more
comprehensive and thorough assessment to the coding region. It is
inevitable that there will be information loss when mapping RNA-
seq data to the array-based reference profiles. For example, of the
top 10 transcript IDs retrieved from the DESeq analysis in Table 1,
3 of them could not be mapped to Affymetrix HG-U133A IDs
used in the reference profiles. Ultimately when the cost of RNA-
seq drops to comparable level with microarray, it will become
more realistic to re-build the reference expression profiles purely
based on the new NGS technology, which in turn probably
requires a more radical change of the mathematical framework
currently employed in the array based connectivity mapping. In
the meantime, the integration attempt we made here contrasted
RNA-Seq extrapolated signatures with those of a traditional
microarray based approach in order to bridge impending costs in
establishing compound reference profiles. Emergent alternative
compound analysis such as the novel L1000 gene expression
analysis offers an attractive platform that has 1000 mRNA
transcripts per Luminex well. It allows for the detection of up to
100 transcripts in many thousands of samples by a flexible and cost
effective multiplex ligation-mediated amplication on a specialised
Luminex FlexMAP [49].
The choice of study carried out here was of a well known RNA-
Seq dataset with which we analysed with an established pipeline in
order to retrieve a list of differentially expressed genes that we
could contrast against a published microarray dataset of similar
design. We first attained a signature with an appropriate false
discovery rate, then the gene signature was perturbed to checked
the robustness of discovered connections to sscMap compounds.
This allowed us to rank the candidate compounds by their
perturbation stability and thus have increased confidence in their
ability to alter the phenotype. The biological outputs from the two
technologies tell a similar story because of the common underlying
phenotype being studied. In order to make the most of the
sensitivity of the RNA-Seq technology, the sequence mapping
tools in the pipeline need to be considered along with appropriate
algorithms for differential expression. Su et al. noted that the
choice of aligners between bowtie, SOAP2 and BWA had a strong
concordance of 98 percent, coupled with the fact that Kvam et al.
noted that the choice of differential expression analysis tool may
vary slightly although edgeR and DESeq performed similarly
[15,17]. As newer NGS analysis software become available
coupled with a decrease in cost of RNA-Seq, future studies using
these techniques will inevitably afford larger sample sizes with
sensitivity and power furthered increased. The flexible and
extensible existing connectivity map software together with new
and emerging tools in connectivity mapping analysis, such as DvD
[50] which utilize Gene Expression Omnibus and Array Express
databases for drug repurposing will undoubtedly become a
valuable resource for discovering candidate therapeutics in cancer
research.
Supporting Information
Table S1 A comprehensive list of differentially ex-
pressed genes from DESeq analysis on the RNA-seq
dataset. Genes are primarily sorted by p-value in ascending
order, and sub-sorted by the absolute value of log2ratio in
descending order in case of equal p-values. All genes with adjusted
p value less than 0.05 are listed here.
(XLSX)
Table S2 A comprehensive list of differentially ex-
pressed genes from EdgeR analysis on the RNA-seq
dataset. Genes are primarily sorted by p-value in ascending
order, and sub-sorted by the absolute value of log2ratio in
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descending order in case of equal p-values. All genes with adjusted
p value less than 0.05 are listed here.
(XLSX)
Table S3 A comprehensive list of differentially ex-
pressed genes from SamR analysis on the microarray
dataset. Genes are primarily sorted by q-value in ascending
order, and sub-sorted by the absolute value of d scores of SamR in
descending order in case of equal q-values. All genes listed here
have a q value less than the cutoff 0.0683, which was the FDR
threshold closest to 0.05 in choosing the delta value in the SamR
analysis.
(XLSX)
Table S4 The gene signature obtained from DESeq
analysis on the NGS dataset. Also included in this table are
the signed ranks of these 10 probesetIDs in the six instances of
reference profiles for cotinine. The magnitude of the rank indicates
the importance of the gene in that reference profile; a minus sign
indicates that the gene was down-regulated in the drug treatment
experiment.
(XLSX)
Table S5 The gene signature obtained from SamR
analysis on the microarray dataset. Also included in this
table are the signed ranks of these 23 probesetIDs in the six
instances of reference profiles for cotinine. The magnitude of the
rank indicates the importance of the gene in that reference profile;
a minus sign indicates that the gene was down-regulated in the
drug treatment experiment.
(XLSX)
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